Individualized prediction of seizure relapse and outcomes following antiepileptic drug withdrawal after pediatric epilepsy surgery

Herm J. Lamberink,Kim Boshuisen,Willem M. Otte,Karin Geleijns,Kees P. J. Braun,the TimeToStop Study Group,
DOI: https://doi.org/10.1111/epi.14020
IF: 6.74
2018-02-15
Epilepsia
Abstract:The objective of this study was to create a clinically useful tool for individualized prediction of seizure outcomes following antiepileptic drug withdrawal after pediatric epilepsy surgery. We used data from the European retrospective TimeToStop study, which included 766 children from 15 centers, to perform a proportional hazard regression analysis. The 2 outcome measures were seizure recurrence and seizure freedom in the last year of follow-up. Prognostic factors were identified through systematic review of the literature. The strongest predictors for each outcome were selected through backward selection, after which nomograms were created. The final models included 3 to 5 factors per model. Discrimination in terms of adjusted concordance statistic was 0.68 (95% confidence interval [CI] 0.67-0.69) for predicting seizure recurrence and 0.73 (95% CI 0.72-0.75) for predicting eventual seizure freedom. An online prediction tool is provided on www.epilepsypredictiontools.info/ttswithdrawal. The presented models can improve counseling of patients and parents regarding postoperative antiepileptic drug policies, by estimating individualized risks of seizure recurrence and eventual outcome.
clinical neurology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is how to individually predict epilepsy recurrence and final outcomes after the withdrawal of antiepileptic drugs in children after epilepsy surgery. Specifically, the study aims to create a clinically useful tool for predicting the risk of epilepsy recurrence and the possibility of long - term seizure - free in children after the successful epilepsy surgery and the discontinuation of antiepileptic drugs (AEDs). This will not only help doctors and patients' families make more informed decisions when considering whether to stop the drugs, but also improve the counseling for patients by estimating the individualized recurrence risk and final outcomes.